AstraZeneca backs up Calquence's potential in mantle cell lymphoma with detailed dataAZ reports 27% increase in PFS for Calquence in MCL - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on June 18, 2024 at 9:44 PM in business No comments 35
Europe taps CSL Seqirus to produce bird flu vaccines for pandemic preparedness efforts - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on June 13, 2024 at 12:28 PM in news No comments 20
GSK exec lauds 'great start' to RSV vaccine uptake as Arexvy nabs label expansion in adults 50-59 - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on June 9, 2024 at 11:00 PM in business No comments 17
ASCO: Bristol Myers' KRAS confirmatory data avoid Amgen's flaws but leave FDA prospect unclearASCO: Bristol Myers' KRAS confirmatory data avoid Amgen's flaws but leave FDA prospect unclear - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on June 3, 2024 at 5:48 AM in business No comments 32
ASCO surprise: J&J's injectable Rybrevant works better than IV - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on June 2, 2024 at 6:12 PM in business No comments 41
FDA approves Tris Pharma's daily nighttime ADHD therapy - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on May 31, 2024 at 6:04 PM in health No comments 23
Novo unveils full results from its GLP-1 trial in CKD - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on May 26, 2024 at 2:54 PM in health No comments 44
Serum Institute deploys first doses of Oxford, Novavax-partnered malaria shot to Africa - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on May 26, 2024 at 12:07 AM in health No comments 52
House's updated biosecurity bill sets 2032 decoupling deadline for industry's work with WuXi AppTec, WuXi Biologics - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on May 11, 2024 at 3:30 PM in business No comments 49
As Vyvanse generics bite, Takeda sets out on $900M restructuring planAs Vyvanse generics bite, Takeda sets out on $900M restructuring plan - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on May 10, 2024 at 4:00 PM in business No comments 9
Novartis slammed again for discrediting pharma industry - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on May 10, 2024 at 11:55 AM in health No comments 56
'Most' cancer meds approved under FDA's accelerated pathway couldn't prove survival benefits after 5 years: study - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on April 9, 2024 at 10:30 PM in business No comments 21
J&J, Legend's Carvykti quickly leaps ahead of BMS' rival CAR-T - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on April 9, 2024 at 12:30 PM in business No comments 61
As AZ hits $45B revenue goal, is Enhertu nearing a plateau? - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on February 9, 2024 at 3:48 PM in business No comments 2
WuXi Biologics plays defense after US bill brands certain Chinese biopharmas as security threats - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on January 30, 2024 at 2:26 PM in business No comments 16
FDA's Peter Marks shares more on CAR-T secondary cancer probe - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on January 26, 2024 at 3:42 PM in business No comments 9
FDA wants classwide boxed warning on all commercial CAR-T therapies amid secondary cancer safety probe - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on January 24, 2024 at 8:27 AM in business No comments 37
Gilead's Trodelvy fails to extend survival in lung cancer study, prompting selloff - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on January 23, 2024 at 2:59 PM in business No comments 43
Jury finds former Pfizer statistician guilty of insider trading - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on January 20, 2024 at 3:24 PM in business No comments 20
JPM24, Day 2: Sanofi plans for life after Dupixent; Sarepta delivers 'better than expected' Elevidys launch - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on January 10, 2024 at 10:06 PM in business No comments 26
2023 drug approvals: After a down year, FDA signs off on a bounty of new meds, including 7 from Pfizer - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on January 3, 2024 at 8:00 AM in business No comments 21
AstraZeneca’s first-in-class FDA approval for Truqap marred by surprise restrictionAstraZeneca's first-in-class FDA approval for Truqap marred by surprise restriction - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on November 18, 2023 at 4:02 PM in business No comments 33
Export of Novo Nordisk's Ozempic could be banned in Germany - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on November 16, 2023 at 4:07 PM in business No comments 37
Delayed FDA nod moves Lilly to crowded ulcerative colitis market - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on October 28, 2023 at 3:10 PM in business No comments 59
Sanofi CEO Hudson's new 'Play to Win' pivot sends stock plungingSanofi CEO Hudson's new 'Play to Win' pivot sends stock plunging - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on October 28, 2023 at 2:57 PM in business No comments 15